Through the acquisition, DiaSorin will gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the group presence in the United States. Additionally, this deal will provide access to Luminex’s applications throughout the life science industry, supporting access to academic and scientific research, expanding engagement with biopharma companies, and increasing access to clinical multiplexing assays for future value-based care projects.
“The acquisition of Luminex represents an important step in the expansion strategy of DiaSorin. Today, we begin a new phase of our growth, that will position DiaSorin as a fully-fledged diagnostic and life science player, that can offer increasingly sophisticated solutions to customers worldwide, also via the integration of the multiplexing technology that Luminex has pioneered globally,” says Carlo Rosa, CEO of DiaSorin. “The future success of the diagnostics and life science sectors will be increasingly determined by the ability to innovate through cutting-edge technologies and solutions. This is the reason why we believe that Luminex is the perfect asset to boost our growth and to turn us into an even more competitive global company. Now, we have to start the process of cultural integration, in which the people of DiaSorin and Luminex will come together with their passion, resourcefulness and professionalism.”